OBJECTIVES: While treatment options for hemophilia A have provided effective disease management and have greatly increased life expectancy, the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation has recommended that “all efforts should be made to remove human albumin from recombinant factor VIII products” to obviate lingering concerns regarding the potential for viral transmission through the use of factor VIII concentrates. To delineate the economic value of a plasma/albumin-free factor VIII product, the fiscal impact attributable to such a product was determined under assumed emergence of a novel infectious blood/plasma borne virus. METHODS: A deterministic model was developed incorporating age-adjusted and proportionally weighted median present-value (1999) annual expense estimates for the management of HIV and AIDS for males, proportion of the hemophilia A population infected due to the emergence of a novel blood (plasma) borne virus (5%), fractional expense of that observed with HIV/AIDS (5%), and the number of bleeding events experience by a given individual per year (i.e., international units of factor VIII administered). Analyses were conducted for individuals weighing 20-, 50-, and 80-kg. RESULTS: Under the assumption of the emergence of a novel infectious blood (plasma) borne virus, the model revealed a savings potential (p<0.05) with the use of a plasma/albumin-free factor VIII product relative to use of a plasma/albumin-containing product, ranging from $0.06 per IU (80 kg male, 12 bleeding episodes/year) to $0.48 per IU (20 kg male, 6 bleeding episodes/year), equating to a potential cost-avoidance of $1742 to $6967 per year (present value). CONCLUSIONS: Antihemophilic Factor (recombinant), Plasma/Albumin-Free Method (rAHF-PFM) offers hemophilia A patients a treatment regimen meeting MASAC recommendations which eliminates the risk of infection from human and animal protein additives with potential economic savings stemming from avoidance of future costs associated with infections transmitted through factor replacement therapy.